Seroprevalence occur rence up to 10% in hyperCORE communities
Capacity to randomize up to 5,000 COVID-19 vaccine patients and 100 treatment/prevention patients per week
Access within our communities to 10,000+ COVID-19 tests administered per day, 5,000+ COVID-19 patients per month, and more than 1M patients in our databases for prevention trials
100,000+ Patients Enrolled in Vaccine Trials
Experience in 40+ Infectious Disease Indications
1,100+ Respiratory Trials Completed ( Including Severe Pneumonia)
Partner Highlights
AGA Clinical Trials is a top enroller in COVID-19 treatment trials.
Benchmark Research has enrolled over 3,000 patients in COVID-19 trials.
FOMAT Medical Research is a top enroller in COVID-19 vaccine and treatment trials and won Oxnard Innovation Award for work on COVID- 19.
IACT Health has enrolled over 1,500 + patients in COVID-19 trials, 47% minorities, and achieved 161% contracted targets.
QCR Clinical Research successfully initiated an outreach initiative with the Omaha Native America Tribe for participation in COVID-19 vaccine trials.